TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06434363: Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 47 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT06434363 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06434363 Rescue Dossier →